As the world is grappling with the deadly COVID-19 pandemic, the race to develop a vaccine has been more crucial than ever before. Amidst this global crisis, India has made significant, strides in developing vaccines, including the latest offering from Zydus Cadila – Zycov-D. This innovative vaccine, which doesn’t require a needle, has created quite a buzz in the medical community. Here’s what you need to know about Zycov-D.
The COVID-19 pandemic has wreaked havoc globally, infecting millions and taking countless lives. While the world has come together to find a solution, the development of a vaccine has been the most pressing issue. In India, the Zydus Cadila has taken up the challenge and has developed the needle-free vaccine, Zycov-D, which is expected to be a game-changer, in the fight against COVID-19.
How does it work?
Zycov-D is a DNA vaccine that uses a plasmid (a small circular piece of DNA) to produce a spike protein found, on the surface of the SARS-CoV-2 virus. This spike protein then triggers an immune response in the body, which helps fight off the virus. The vaccine is administered using a needle-free device called the PharmaJet® Stratis® Needle-Free Injection System, which uses a high-velocity fluid stream, to deliver the vaccine into the muscle.
Advantages of the needle-free vaccine:
One of the significant advantages of Zycov-D is that it eliminates the use of needles, which makes it less painful and more convenient. The vaccine also reduces the risk of needle-stick injuries, which can be hazardous to healthcare workers. The needle-free device used to administer the vaccine is easy to use, & it eliminates the need for trained medical professionals to administer the vaccine.
Efficacy and safety:
Zydus Cadila has conducted extensive clinical trials to evaluate the efficacy and safety of Zycov-D. The phase III clinical trials showed that the vaccine was 66.6% effective against symptomatic COVID-19 cases. The vaccine has also been found to be safe and well-tolerated, with minimal side effects such as injection site pain, fatigue, & headache.
Zycov-D has received emergency use authorization (EUA) from the Drug Controller General of India (DCGI) and is now available for use in the country. Zydus Cadila has also applied for emergency use authorization from other regulatory authorities, including the World Health Organization (WHO).
The development of a needle-free vaccine such as Zycov-D marks a significant, breakthrough in the fight against COVID-19. The vaccine’s convenience, safety, and efficacy make it a viable option for mass vaccination drives in India and beyond. As the world continues to grapple with the pandemic, it’s reassuring to know that Indian, pharmaceutical companies are at the forefront of finding a solution.